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Abstract
Background: T7 based linear amplification of RNA is used to obtain sufficient antisense RNA for
microarray expression profiling. We optimized and systematically evaluated the fidelity and
reproducibility of different amplification protocols using total RNA obtained from primary human
breast carcinomas and high-density cDNA microarrays.
Results: Using an optimized protocol, the average correlation coefficient of gene expression of
11,123 cDNA clones between amplified and unamplified samples is 0.82 (0.85 when a virtual array
was created using repeatedly amplified samples to minimize experimental variation). Less than 4%
of genes show changes in expression level by 2-fold or greater after amplification compared to
unamplified samples. Most changes due to amplification are not systematic both within one tumor
sample and between different tumors. Amplification appears to dampen the variation of gene
expression for some genes when compared to unamplified poly(A)+ RNA. The reproducibility
between repeatedly amplified samples is 0.97 when performed on the same day, but drops to 0.90
when performed weeks apart. The fidelity and reproducibility of amplification is not affected by
decreasing the amount of input total RNA in the 0.3–3 µg range. Adding template-switching primer,
DNA ligase, or column purification of double-stranded cDNA does not improve the fidelity of
amplification. The correlation coefficient between amplified and unamplified samples is higher when
total RNA is used as template for both experimental and reference RNA amplification.
Conclusion: T7 based linear amplification reproducibly generates amplified RNA that closely
approximates original sample for gene expression profiling using cDNA microarrays.
Background
Gene expression profiling using complementary DNA
(cDNA) microarrays is being applied for multiple purpos-
es such as defining the taxonomy of different molecular
subtypes of human breast and other cancers [1–10] and
discovering biomarkers and therapeutic targets [11,12]. A
limitation of the use of this technology is that small spec-
imens of human tissue, such as obtained by core needle or
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fine needle aspiration (FNA) biopsies, may not be suffi-
cient for microarray hybridization using direct labelling
protocols. Typical microarray labelling procedures require
2–4 µg poly(A)+ RNA or 25–50 µg total RNA per cDNA
microarray. This amount of poly(A)+ RNA or total RNA
can be obtained from samples of human tissue that weigh
greater than 50–100 mg. However, core needle biopsies of
breast cancers, for example, weigh in the 10–25 mg range
and yield only 3–15 µg of total RNA. Small tumors iden-
tified using early detection strategies may thus be too
small to excise a specimen with enough RNA for microar-
ray analysis. A pilot study by Assersohn et al. [13] showed
that only 15% of FNA samples from human breast cancers
produced sufficient mRNA for expression array analysis.
One approach to low specimen RNA input has been to use
indirect labelling techniques to increase fluorescence sig-
nal intensity, such as with aminoallyl nucleotides. Al-
though less expensive, we and other colleagues have
found that indirect labelling techniques are not always re-
liable compared to direct labelling methods. For valuable
tumor specimen, reliability is paramount. A very recent re-
port used amino C6dT-modified random hexamers to
prime cDNA synthesis in conjunction with aminoallyl-
dUTP and increased fluorescence intensity enough such
that as little as 1 µg of total RNA from cell lines gave suffi-
cient signal for cDNA microarray hybridization [14]. The
reliability of this method with human tumor specimen
warrants further testing.
RNA amplification techniques have been developed to ad-
dress the need for sufficient RNA from tiny specimen for
microarray hybridization. Other examples of specimen re-
quiring amplification for genome-wide characterization
of gene expression include purified populations of cells
obtained by either flow cytometry, laser capture microdis-
section, breast ductal or bronchial lavage, or microendos-
copy. Although one group has used unamplified total
RNA extracted from ~2 × 104 microdissected cells for hy-
bridization on 5000 clone membrane-based arrays [15],
most groups perform RNA amplification for this purpose
[16–18], especially when using high-density slide-based
arrays.
The most commonly used mechanism for RNA amplifica-
tion is a T7 based linear amplification method first devel-
oped by Van Gelder, Eberwine and coworkers [19–21].
This method utilizes a synthetic oligo(dT) primer contain-
ing the phage T7 RNA polymerase promoter to prime syn-
thesis of first strand cDNA by reverse transcription of the
poly(A)+ RNA component of total RNA. Second strand
cDNA is synthesized by degrading the poly(A)+ RNA
strand with RNase H, followed by second strand synthesis
with E. coli DNA polymerase I. Amplified antisense RNA
(aRNA) is obtained from in vitro transcription of the dou-
ble-stranded cDNA (ds cDNA) template using T7 RNA
polymerase. Several protocols based on this mechanism
have been developed and used in microarray analyses
[16,22–28].
In spite of the increasing use of T7 based linear amplifica-
tion techniques in the study of human disease, systematic
evaluation of the fidelity and the reproducibility of ampli-
fication mechanisms has been limited. Such information
is important to determine how well the amplified sample
resembles the unamplified sample and the validity of ap-
plying this technique to the study of human tissues. A
study by Wang and Miller et al. [24] described a T7 based
amplification protocol modified with a template-switch-
ing (TS) primer used to theoretically generate a full-length
ds cDNA. The gene expression of amplified total RNA
from melanoma cell lines hybridized to 2000 gene micro-
arrays was compared to that of unamplified total or po-
ly(A)+ RNA using cluster analysis and determining the
number of outlier genes between single experiments. Ap-
proximately 3–6% of genes were discordant outliers when
analyzed using 3-fold or greater expression ratios in at
least one hybridization and compared between total RNA,
mRNA, and different amounts of input aRNA. Hu and co-
workers [27] compared amplified and unamplified sam-
ples using total RNA obtained from human glioma cell
lines and 2300 clone microarrays (printed with duplicates
on the same array) to evaluate a similar T7 based protocol
with a TS mechanism adopted from Wang and Miller et al.
[24]. Their results were based on nine microarray experi-
ments and showed concordance between amplified and
unamplified samples, verifying four expressed and two
differentially expressed genes using Northern and Western
blotting and immunohistochemical assay.
Since there are multiple T7 based amplification protocols
in use, questions remain regarding the effects of differenc-
es between these protocols and how these differences
translate when applied to solid tumors rather than cell
lines on a genome-wide scale. A study from Incyte Ge-
nomics [25] examined gene expression of kidney vs. pla-
centa RNA and RNA from matched normal and tumor
renal tissue using their own T7 based amplification kit
(not employing a TS primer) and 9700 clone cDNA
microarrays. They found that a differential expression ra-
tio cut-off of greater than or equal to 2-fold produced ex-
cellent correlation between samples amplified with
different amounts of input poly(A)+ RNA but that a 3-fold
differential expression ratio threshold should be set for
comparing ratios between amplified and unamplified
mRNA. Decreasing the input of tissue lysate increased
gene expression discordance between amplified and un-
amplified samples. As more human tissues were tested,
single round amplification produced a 200- to 500-fold
yield, lower than the 700-fold yield originally found inBMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/31
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their study and lower than yields reported in amplifica-
tion studies using cell cultures.
The differences between several T7 based linear amplifica-
tion protocols are mainly the following: 1. whether a tem-
plate-switching mechanism is used in the synthesis of
second strand cDNA, 2. what enzymes are used in the syn-
thesis of second strand cDNA, 3. how ds cDNA is purified
("cleaned up") prior to in vitro transcription, and 4. how
in vitro transcription is performed. Information regarding
the effects of these differences on the fidelity or reproduc-
ibility of amplification should help eliminate both unnec-
essary procedures and those actually detrimental to
amplification. Determination of the range of input total
RNA necessary to achieve reasonable fidelity and repro-
ducibility is crucial for researchers dealing with very small
specimens of human tissue.
To answer these questions and to define an optimal pro-
tocol for T7 based linear amplification, we carried out a
series of amplification reactions under different condi-
tions using total RNA isolated from primary human breast
carcinomas. The amplified samples were compared to un-
amplified samples on high-density cDNA microarrays
containing 41,931–42,602 clones. We evaluated the ef-
fects of TS primer in second strand cDNA synthesis, DNA
ligase activity in second strand cDNA synthesis, column
purification of ds cDNA, and in vitro transcription time
on the fidelity and reproducibility of amplification and
the yield of aRNA. The effect of diminishing amounts of
input total RNA was also tested.
Results and Discussion
Variation in cDNA microarray analysis of gene expression 
using unamplified poly(A)+ RNA
In order to assess the reproducibility of microarray hy-
bridization using standard methods, poly(A)+ RNA was
isolated from both primary breast carcinoma BC2 and
Universal Human Reference total RNA (Stratagene®). The
BC2 poly(A)+ RNA labelled with Cy5 and the reference
poly(A)+ RNA labelled with Cy3 were hybridized on five
42,000 clone cDNA microarrays. 16,333 clones had a sig-
nal greater than 50% above background on all five arrays.
Three hybridizations were done on the same day using ar-
rays from the same print batch and the average correlation
coefficient between any two hybridizations was 0.97 ±
0.01, demonstrating a high reproducibility between paral-
lel hybridizations done on the same day. Another two hy-
bridizations were performed using poly(A)+ RNA isolated
from BC2 total RNA three months later and a different
print batch of microarrays. The correlation coefficient be-
tween these two arrays was 0.95, similar to the average
Table 1: Correlation coefficients of amplified and unamplified expression levels of 14,044 genes selected according to the described cri-
teria. Amplifications with or without TS primer and with two different ds cDNA cleanup protocols were performed on BC91 total RNA.
Column for ds cDNA cleanup Bio-6 G-50
Reference RNA amplified Total RNA Poly(A)+ RNA Total RNA Poly(A)+ RNA
w/o TS Virtual 0.84 (n = 2) 0.77 (n = 4) 0.82 (n = 2) 0.80 (n = 4)
Average 0.83 ± 0.01 (n = 2) 0.73 ± 0.07 (n = 4) 0.81 ± 0.00 (n = 2) 0.76 ± 0.05 (n = 4)
TS Virtual 0.81 (n = 2) 0.79 (n = 3) 0.77 (n = 1) 0.71 (n = 2)
Average 0.80 ± 0.05 (n = 2) 0.74 ± 0.04 (n = 3) 0.68 ± 0.02 (n = 2)
Table 2: Efficacy of amplification using 3 µg total RNA from BC91 and different ds cDNA cleanup methods, with or without TS primer.
Column used for ds cDNA cleanup Bio-6 G-50
Amplification Protocol TS w/o TS TS w/o TS
Yield of aRNA (µg) 7.6 ± 1.0 (n = 5) 11.1 ± 2.2 (n = 3) 8.9 ± 3.8 (n = 6) 10.0 ± 5.1 (n = 6)
Fold of amplification 253 ± 33 370 ± 73 297 ± 126 333 ± 170BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/31
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correlation coefficient of the first three arrays. However,
when the unamplified poly(A)+ RNA arrays performed
weeks apart from different print batches were compared,
the average correlation coefficient dropped to 0.89 ± 0.01,
indicating that experimental variations due to differences
in microarray printing, poly(A)+ RNA isolation, and RNA
labelling and hybridization contribute a small but detect-
able change in results.
In order to minimize experimental variations, we created
a virtual poly(A)+ RNA expression array that idealizes the
gene expression of sample BC2 by using the average ex-
pression level of each clone over multiple hybridizations.
By "expression level" we mean the normalized log (base2)
ratio of signal intensities of Cy5 (experimental sample) to
Cy3 (reference) fluorescence. The idealized expression
profile from the poly(A)+ RNA virtual array is used as our
unamplified "gold standard" for data analyses involving
BC2. The correlation coefficient between each individual
poly(A)+ RNA array and the gold standard ranges from
0.95–0.97, similar to that observed between hybridiza-
tions performed on the same day. The gold standard vir-
tual array therefore represents well-measured gene
expression in the primary tumor and minimizes individu-
al experimental variations.
Template-switching does not affect the fidelity of amplifi-
cation
As previously mentioned, a protocol based on T7 based
linear amplification published by Wang, Miller and cow-
orkers [24] incorporated a TS mechanism [29] in the syn-
thesis of second strand cDNA at the 5' end in order to
generate full-length ds cDNA. This was speculated to be of
advantage in the hybridization of unmapped sequences
spotted on arrays and to enable higher temperature cDNA
synthesis that would enhance sequence specificity. How-
ever, no experimental evidence was provided to support
the idea that the TS mechanism increases the fidelity of
amplification.
To determine whether the addition of TS primer improves
the fidelity of amplification, we compared gene expres-
sion profiles of aRNA amplified in the presence or absence
of TS primer with expression profiles of unamplified po-
ly(A)+ RNA. Total RNA isolated from primary breast carci-
noma BC91 and reference total RNA were amplified with
or without TS primer using the Wang-Miller protocol [24],
except that aRNA was purified using an RNeasy® kit (Qia-
gen®). A virtual "gold standard" poly(A)+ RNA array was
created for BC91 using the average expression level of four
hybridization replicates of unamplified poly(A)+ RNA. A
"virtual correlation coefficient" for a given amplification
protocol was obtained by comparing the virtual amplified
array (averaged expression level for each clone from mul-
tiple amplified samples) to the virtual gold standard un-
amplified array for BC91. To determine the correlation
between individual amplified samples and the gold stand-
ard, an "average correlation coefficient" for a given ampli-
fication protocol was also calculated (the sum of
correlation coefficients of individual amplified samples
with the gold standard divided by the number of ampli-
fied samples tested for each condition).
As shown in Table 1, using aRNA amplified from total
RNA as reference, the expression profiles obtained in the
absence of TS primer correlated with the gold standard
slightly better than in the presence of TS primer, although
the difference was not statistically significant. When po-
ly(A)+ RNA rather than total RNA was amplified as refer-
ence, the correlation with the gold standard was slightly,
but not statistically significantly, better with TS primer
(Table 1). The correlation coefficient using aRNA ampli-
fied from total RNA as reference is higher than using
aRNA amplified from poly(A)+ RNA as reference regard-
less of whether TS primer is used. This suggests that when
total RNA from a tumor sample is amplified for microar-
ray analysis, the reference RNA should also be amplified
from total RNA.
The yield of aRNA amplified from BC91 total RNA using
different protocols is shown in Table 2. Assuming 1% of
the total RNA is poly(A)+ RNA, a 253 and 370-fold ampli-
fication was observed in the presence and absence of TS
primer, respectively. The yield of aRNA amplified from to-
tal RNA which are generated from cultured cell lines was
2- to 3-fold higher than when the primary tumor total
RNA was amplified (data not shown).
These experiments demonstrate that the TS mechanism
does not increase the fidelity of amplification, and there-
fore can be eliminated from the protocol. The reasons for
the limited effect of the TS mechanism on the correlation
coefficients probably are: 1) the second strand cDNA syn-
thesis primed by the TS primer probably represents a
small fraction, while the majority of the synthesis is self-
primed or primed by small pieces of RNA generated by
RNase H; and 2) adding a few base pairs to the ds cDNA
prior to in vitro transcription does not change the aRNA
significantly enough to affect the array hybridization.
DNA ligase activity is not required for amplification
Amplification protocols that do not include DNA ligase in
second strand cDNA synthesis generate the same length
aRNA (ranging from 0.2 kb to 6 kb, data not shown) as
generated from a widely used T7 based amplification pro-
tocol developed by Affymetrix®[26] which uses E. coli
DNA ligase. The correlation coefficient between amplified
and unamplified sample and the yield of aRNA amplified
without DNA ligase are high enough to suggest that DNA
ligase activity is not necessary for RNA amplification inBMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/31
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microarray analysis. For confirmation, we omitted DNA
ligase from the protocol developed by Affymetrix® and
compared the expression profiles of the resulting aRNA to
aRNA obtained using the standard Affymetrix® protocol
that includes DNA ligase. The correlation coefficient be-
tween amplified and unamplified samples is slightly high-
er in the absence of ligase (Table 3), supporting our
previous conclusion that ligase is not required for total
RNA amplification in cDNA microarray analysis. Howev-
er, the yield of aRNA is higher when ligase is used, suggest-
ing that ligase may play a role in improving the efficiency
of amplification.
Column cleanup of ds cDNA does not improve the fidelity 
of amplification, but decreases the yield of aRNA
In the Wang-Miller protocol [24], ds cDNA is purified us-
ing a Bio-6 column (Bio-Rad). A drawback to this method
is that the cDNA is eluted with a large volume and needs
to be concentrated into a much smaller volume by lyophi-
lization prior to in vitro transcription. This is a time-con-
suming step, especially when large numbers of samples
are processed. To eliminate the lyophilization step from
the protocol, we used an alternative column–the Sepha-
dex™ G-50 column–to filter out free nucleotides from the
ds cDNA after completion of the second strand synthesis
reaction. The ds cDNA is then precipitated following phe-
nol-chloroform extraction and re-suspended in proper
volume for in vitro transcription. The correlation coeffi-
cient between amplified and unamplified samples and the
yield of aRNA using this less time-consuming modifica-
tion are similar to that using the Wang-Miller protocol
(Tables 1 and 2).
We further explored the question of what effects the ds
cDNA column cleanup step itself had on amplification.
We amplified total RNA from tumor BC2, either with or
without the cleanup step of Sephadex™ G-50. Seven am-
plifications were done on different dates with the Sepha-
dex™ G-50 column and five amplifications were done
without this cleanup step. Both the virtual and the average
correlation coefficients using the column are slightly low-
er than without it (Table 4), suggesting that the column
cleanup does not improve the fidelity of amplification.
Moreover, the yield of aRNA is significantly higher with-
out the column purification of ds cDNA, suggesting some
loss of ds cDNA on the column. Since the column had a
negative effect on amplification by decreasing the yield of
aRNA without improving the fidelity of amplification, we
eliminated this step from our protocol.
Table 3: Effect of DNA ligase on the fidelity of amplification.a,b
Protocol Affymetrix Affymetrix w/o ligase
Number of amplifications 6 5
Correlation coefficient Virtual 0.84 0.86
Average 0.79 ± 0.04 0.82 ± 0.04
Yield of aRNA (µg) 24.1 ± 4.7 19.2 ± 5.9
Fold of amplification 803 ± 157 640 ± 197
aData were obtained from comparing expression level of 13,783 clones using the described selection criteria. bInput BC2 total RNA is 3 µg.
Table 4: Effect of column cleanup on the fidelity and yield of amplification.a,b
Protocol G-50 cleanup w/o G-50 cleanup
Number of amplifications 7 5
Correlation coefficient Virtual 0.83 0.85
Average 0.79 ± 0.03 0.81 ± 0.02
Yield of aRNA (µg) 11.9 ± 2.8 15.9 ± 2.7
Fold of amplification 397 ± 93 530 ± 90
aData were obtained from comparing expression level of 12,305 clones using the described selection criteria. bInput BC2 total RNA is 3 µg and 
amplification was done without TS primer.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/31
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Effect of in vitro transcription time on the fidelity of RNA 
amplification
To determine the effect of in vitro transcription time on
amplification, duplicate reactions were performed at 37°C
for 2, 3, 4, 5 and 6 hours. Two additional 5-hour incuba-
tion reactions were stored at 4°C overnight to determine
the effect of low temperature incubation on amplification.
The virtual correlation coefficient is slightly higher for the
5-hour incubation at 37°C (Figure 1A). However, in vitro
transcription for 5 hours at 37°C plus overnight incuba-
tion at 4°C gives the highest yield of aRNA (Figure 1B).
Since the yield of aRNA at any time point is sufficient for
multiple hybridizations, we decided to use 5-hour incuba-
tion at 37°C for all subsequent amplifications.
Evaluation of the fidelity of T7 based linear amplification 
protocols
To systematically evaluate the fidelity of T7 based ampli-
fication, we compared the correlation coefficient obtained
from four different protocols. The correlation coefficients
of individual samples amplified using different protocols
with the gold standard range from 0.74–0.86 (Figure 2).
The scatter plots comparing the gene expression of the vir-
tual amplified samples for each protocol with the unam-
plified gold standard are shown in Figure 3, with the
virtual correlation coefficients ranging from 0.83–0.86.
The differences in correlations obtained using different
protocols are not statistically different by Student's t-test,
demonstrating that differences in gene expression for
samples amplified using different protocols are minor.
Our results also suggest that the level of bias introduced
into gene expression profiling by amplification is relative-
ly low; expression profiles obtained using aRNA provide a
close approximation of the true expression profile of the
original sample. To assess the biases of amplification
quantitatively, we calculated the number and percentage
of genes with expression level change by 4- or 2-fold after
amplification. The biases of amplification by different
protocols are similar. Specifically, less than 0.2% of
11,123 genes (12–15 genes) changed their expression lev-
el by 4-fold or greater and less than 6% (306–594 genes)
changed expression by 2-fold or greater after amplifica-
tion. With the Jeffrey lab protocol, less than 4% of genes
showed changes in expression level by 2-fold or greater.
Of the genes that changed, 7 genes and 139 genes changed
their expression in all four protocols in the same direction
greater than 4-fold and 2-fold, respectively. Also, the vir-
tual correlation coefficients between different protocols
are high (average 0.95) (Figure 3), suggesting that slight
differences in protocols based on T7 linear amplification
mechanism do not affect the correlation of amplified
samples to unamplified samples. These results suggest the
conclusion that aRNA provides a close approximation of
the true expression profile of the original sample.
We present here a components of variance model for ex-
plaining the different sources of variation in the amplifi-
cation protocols (see Statistical Appendix, additional file
1). The expression measurement for a gene for a specific
array/protocol/sample can be broken down as
X = Z + e, where
X is the measured expression value
Z is the "true" expression that does not change under rep-
lication, and
e is the measurement error that does change under repli-
cation.
While we cannot estimate Z and e directly, we can esti-
mate their variances from the data. For the four different
amplified protocols and the unamplified arrays, the rele-
vant variances are estimated in Table 5. The variance of the
true expression (Var Z) ranges from 0.623–0.661 for the
amplified protocols and is 0.726 for the unamplified ar-
rays. The variance of the measurement error (Var e) ranges
from 0.055–0.102 for the amplified protocols and is
0.059 for the unamplified arrays. The estimates of Var Z
were obtained by averaging the pairwise covariances of
the replicates within each protocol, and the estimates of
Var e by using the within-protocol variance. (While the
variance of a collection of numbers measures how much
they vary about their mean, the covariance of two sets of
numbers measures how much they vary with respect to
each other. See Statistical Appendix for more details). We
notice that Var Z for unamplified poly(A)+ RNA is larger
than all of the others, indicating a dampening effect on
gene expression by amplification. Measurement error var-
iance is lowest for the Jeffrey lab protocol.
The covariances between the different Zs for the different
methods (estimated from the virtual arrays) are shown in
Table 6. The off-diagonal elements of Table 6 are the cov-
ariances; the diagonal elements are the variances of the
virtual arrays. We notice that covariances among the am-
plified protocols, which range from 0.62 to 0.66, are high-
er than their covariances with the unamplified arrays,
which range between 0.57 and 0.61. Furthermore, the var-
iances of the amplified protocols (0.63 to 0.68) are lower
than that of the unamplifed (0.74).
This suggests the following further breakdown:
Z = Zc + Zs, where
Zc is a common expression component, with variance
about 0.6, andBMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/31
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Figure 1
Effects of in vitro transcription time on the fidelity of T7 based amplification and the yield of aRNA amplified
from BC2 total RNA. Average correlation coefficients between amplified samples vs. unamplified poly(A)+ RNA at each
time point are shown in A and average yields of aRNA from each time point in B.
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Zs is a specific expression component, with variance about
0.04 for the amplified arrays and 0.14 for the unamplified
arrays.
Therefore, the amplified expression values for genes on an
array are largely the same as on the unamplified array. The
component of variation in which they differ appears to be
common for all amplified protocols, and shows a much
higher variance in the unamplified arrays. The effect of
amplification can be summarized by saying that it has a
dampening effect on the true expression of some genes
(decreased variance in gene expression – see Figure 4).
A recent report compared amplified expression profiles of
different primary breast tumors using Affymetrix® arrays
[30]. Unger et al. found that correlation coefficients be-
tween gene expressions in different tumors revealed by
aRNA ranged between 0.71–0.89. However, gene expres-
sion was not measured using unamplified poly(A)+ RNA
from these different tumors, raising the question of
whether the observed fairly high correlation between di-
verse tumors was due to amplification bias. To answer this
question, we compared the correlation coefficients be-
tween gene expression profiles of different tumors deter-
mined either with unamplified poly(A)+ RNA or aRNA
amplified using our protocol (Table 7). The correlation
coefficients between BC2 and BC91 measured using po-
ly(A)+ RNA or aRNA are the same, 0.55. Moreover, the
correlation between differences in gene expression be-
tween amplified and unamplified samples for different tu-
mors is weak (Figure 4), suggesting that genes that differ
through amplification depend on the sample rather than
on systematic changes from amplification. Our results
demonstrate that different primary breast tumors are not
closely related to each other in gene expression profiles,
and amplification does not affect the correlation of gene
expression between different tumors. Amplification is
Figure 2
Box graph of correlation coefficients of the gene expression levels for 11,123 clones, comparing individual
amplified samples to the gold standard of BC2 (idealizing unamplified poly(A)+ RNA). Each closed circle repre-
sents the correlation coefficient for each individual sample amplified with a particular protocol to the gold standard. The aver-
age and virtual correlation coefficients of the replicate samples for each protocol are shown below the graph.
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Figure 3
Scatterplot matrix using average expression ratios of multiple replicate amplifications for each protocol and
the gold standard. The X-axis and Y-axis show virtual gene expression level [normalized log(base2) fluorescence intensity
ratio of sample to reference averaged over multiple arrays] measured using aRNA amplified by different protocols or unampli-
fied poly(A)+ RNA as labelled. The last column of plots shows each amplification protocol (Y-axis) vs. gold standard (X-axis).
The correlation coefficient for each pair is listed in each plot. The orange and blue shaded regions indicate more than a two-
fold difference between the virtual expression values for each protocol being compared.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/31
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therefore suitable for comparison of gene expression pro-
files among large sample sets.
Evaluation of reproducibility of T7 based linear amplifica-
tion
Another important aspect of RNA amplification is the de-
gree of reproducibility. To evaluate this, we calculated the
correlation coefficients between individual amplified
samples. The correlation coefficients between individual
hybridizations done on the same day for poly(A)+ RNA
averaged 0.97 and for aRNA amplified on the same day
averaged from 0.91–0.98 (Table 8). The correlation coef-
ficients between individual hybridizations done on differ-
ent days averaged 0.89 for poly(A)+ RNA and 0.85–0.90
for aRNA amplified from total RNA on different days. The
reproducibility of our protocol is slightly better than that
using other protocols. Notably, when samples are ampli-
fied on the same day, the correlations are significantly
higher than when samples are amplified on different days.
In addition, samples amplified with protocols omitting
ligase activity give higher reproducibility regardless of
whether they are amplified on the same day or not.
The effect of the amount of input total RNA on amplifica-
tion
To determine the effect of the amount of input total RNA
on single round amplification, we amplified different
amounts of total RNA, 3 µg, 1 µg, 300 ng, 100 ng, 30 ng
and 10 ng, using different amounts of T7 primer accord-
ing to the quantity of input total RNA (Table 9). When the
input total RNA is lower than 300 ng, the yield of aRNA
for is lower than the standard quantity required for one
hybridization (3 µg). At amounts greater or equal to 300
ng, the correlation coefficients between amplified and un-
amplified samples and among amplified samples remain
about the same. The fold of amplification increases with
smaller quantities of template RNA, but the absolute yield
of aRNA decreases. Therefore, within the range of 0.3–3
µg total RNA, decreasing the input RNA does not affect the
fidelity and reproducibility of amplification.
All original microarray data may be accessed at the RNA
Amplification for Microarrays website  [http://genome-
www.stanford.edu/breast_cancer/amplification/].
Conclusions
In conclusion, T7 based linear amplification generates
high fidelity aRNA for gene expression profiling using
high-density cDNA microarrays. The average correlation
coefficient between amplified and unamplified samples is
0.82 with less than 4% of genes showing changes in ex-
pression level by 2-fold or greater using the optimized
(Jeffrey lab) protocol. The correlation to unamplified po-
ly(A)+ RNA increases to 0.85 when experimental variabil-
ity is minimized by configuring multiple amplified
samples into a virtual array. Reproducibility between sam-
Table 5: Variance of true gene expression (Var Z) and measurement error (Var e) for each of the different amplified protocols and the 
unamplified arrays.
Affymetrix Affymetrix w/o ligase Jeffrey lab with G-50 
cleanup
Jeffrey lab Poly(A)+ RNA
Var Z 0.661 0.658 0.623 0.661 0.726
Var e 0.102 0.066 0.078 0.055 0.059
Table 6: Covariances between the "true" gene expression for the different amplification protocols, estimated from the virtual arrays. 
The diagonal of the table contains the variances for the techniques.
Affymetrix Affymetrix w/o 
ligase
Jeffrey lab with G-50 
cleanup
Jeffrey lab Poly(A)+ RNA
Affymetrix 0.68 0.66 0.62 0.63 0.60
Affymetrix w/o ligase 0.66 0.67 0.62 0.64 0.61
Jeffrey lab with G-50 cleanup 0.62 0.62 0.63 0.64 0.57
Jeffrey lab 0.63 0.64 0.64 0.67 0.60
Poly(A)+ RNA 0.60 0.61 0.57 0.60 0.74BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/31
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ples amplified with this technique is high, especially
when performed on the same day rather than weeks apart.
Amplification produces a dampening effect on gene ex-
pression variation.
Methods
Tissue acquisition
Two primary breast carcinomas, BC2 and BC91, in which
more than 90% of the breast epithelial cells were cancer
cells, were chosen for experiments in this study. The spec-
imens were frozen in either liquid nitrogen (BC2) or on
dry ice (BC91) within 30 minutes following devasculari-
zation and stored at -80°C. Frozen sections were cut from
primary breast carcinoma specimens and stained with he-
matoxylin and eosin to confirm tumor content.
Figure 4
Scatterplot of the t-statistics (the numerical score underlying a t-test) comparing the differences in gene
expression between amplified and unamplified RNA for BC2 (X-axis) and BC91 (Y-axis). The tests were based on
7 amplified total RNA and 5 unamplified poly(A)+ RNA samples for BC2, and 2 amplified total RNA and 4 unamplified poly(A)+
RNA samples for BC91.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/31
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RNA preparation
Total RNA was isolated from primary tumor tissue using
TRIzol® solution (Invitrogen™) following homogeniza-
tion using a PowerGen Model 125 (Fisher Scientific). Po-
ly(A)+ RNA was isolated from total RNA with the
FastTrack 2.0 kit (Invitrogen™). The concentration of total
RNA and poly(A)+ RNA was determined using a GeneSpec
I spectrophotometer (Hitachi) and the integrity of total
RNA and poly(A)+ RNA was assessed using a 2100 Bioan-
alyzer (Agilent).
Table 7: Correlation between expression levels of different tumors (BC2 and BC91) determined with both poly(A)+ RNA and aRNA for 
each tumor.a,b
Virtual correlation coefficient Number of arrays
BC2 poly(A)+ RNA vs. BC91 poly(A)+ RNA 0.55 5 vs. 4
BC2 aRNA vs. BC91 aRNA 0.55 2 vs. 2
BC2 aRNA vs. BC2 poly(A)+ RNA 0.84 2 vs. 5
BC91 aRNA vs. BC91 poly(A)+ RNA 0.82 2 vs. 4
BC2 aRNA vs. BC91 poly(A)+ RNA 0.52 2 vs. 4
BC91 aRNA vs. BC2 poly(A)+ RNA 0.46 2 vs. 5
aData were obtained from comparing expression level of 11,929 clones using the described selection criteria. bData were obtained using the Jeffrey 
lab protocol with G-50 cleanup.
Table 8: Evaluation of the reproducibility of T7 based amplification.a,b
Protocol Affymetrixc Affymetrix w/o 
ligase
Jeffrey lab with G-50 Jeffrey lab poly(A)+ RNA
Average correlation 
coefficient
Same day 0.91 ± 0.04 (n = 3) 0.98 (n = 2) 0.95 ± 0.01 (n = 3) 0.97 (n = 2) 0.97 ± 0.01 (n = 3)
Different 
day
0.84 ± 0.05 (n = 3) 0.88 ± 0.05 (n = 3) 0.88 ± 0.03 (n = 4) 0.90 ± 0.03 (n = 
3)
0.89 ± 0.03 (n = 2)
Overall 0.86 ± 0.05 (n = 6) 0.89 ± 0.05 (n = 5) 0.89 ± 0.03 (n = 7) 0.91 ± 0.03 (n = 
5)
0.92 ± 0.05 (n = 5)
aData were obtained from comparing expression level of 11,123 clones using the described selection criteria. bAmplification was done using 3 µg 
BC2 total RNA. cNote that hybridizations were performed on Stanford printed cDNA microarrays, not Affymetrix arrays.
Table 9: The effect of the amount of template BC2 total RNA on the fidelity, reproducibility and yield of amplification.a
Input total RNA 3 µg1   µg 300 ng 100 ng 30 ng 10 ng
T7 primer used (µg) 0.5 0.2 0.1 0.1 0.1 0.1
Average correlation coefficient Amplified vs. gold standard 
(fidelity)
0.80 ± 0.04 (n = 4) 0.81 ± 0.05 (n = 3) 0.84 ± 0.05 (n = 2) ND ND ND
Amplified vs. amplified 
(reproducibility)
0.92 ± 0.04 (n = 4) 0.88 ± 0.04 (n = 3) 0.90 (n = 2) ND ND ND
Yield (µg) 15.2 ± 5.6 (n = 4) 7.4 ± 4.6 (n = 3) 3.1 ± 1.6 (n = 2) 0.60 ± 0.3 
(n = 2)
0.33 ± 0.2 
(n = 3)
0.11 ± 0.1 
(n = 3)
Fold of amplification 507 ± 186 740 ± 460 1033 ± 530 600 ± 300 1100 ± 
667
1100 ± 
1000
aData were obtained from comparing expression levels of 13,164 clones using the described selection criteria. ND = not determined due to insuffi-
cient yield of aRNA for microarray hybridization after single round of amplification.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/31
Page 13 of 15
(page number not for citation purposes)
RNA amplification
The amplification of total RNA or poly(A)+ RNA was per-
formed based on a previously described protocol [24]
with our modifications.
For first strand cDNA synthesis, 3 µg (unless otherwise
specified) tumor total RNA, Universal Human Reference
total RNA (Stratagene®), or 150 ng poly(A)+ RNA was
mixed with 1 µg Eberwine primer (Operon®) in RNase-
free water to a total volume of 9 µl. The RNA/primer mix-
ture was denatured at 70°C for 3 min and cooled on ice
for 2 min, followed by adding: 4 µl of 5X first strand buff-
er (Invitrogen™), 2 µl 0.1 M DTT, 1 µl RNasin® (40 U/µl,
Promega™), 2 µl 10 mM dNTP, and 2 µl Superscript™ II
(200 U/µl, Invitrogen™), and incubated at 42°C for 1.5
hours.
Second strand cDNA synthesis was performed by mixing
the first strand synthesis reaction with 106 µl RNase-free
water, 15 µl 10X Advantage™ PCR buffer (Clontech), 3 µl
10 mM dNTP mix, 3 µl Advantage™ cDNA polymerase
mix (Clontech), and 1 µl RNase H (2 U/µl, Invitrogen™).
The reaction was incubated at 37°C for 5 min to digest
RNA, followed by 94°C for 2 min to activate the Advan-
tage™ cDNA polymerase, 65°C for 1 min to prime and
75°C for 30 min to extend the second strand cDNA. The
reaction was stopped by the addition of 7.5 µl 1 M NaOH/
2 mM EDTA and incubated at 65°C for 10 min.
ds cDNA was extracted with an equal volume of phe-
nol:chloroform: isoamyl alcohol (25:24:1), transferred to
a Phase Lock Gel™ tube (Eppendorf) and centrifuged at
16,000 g for 5 min. The ds cDNA (aqueous layer) was
transferred to a new tube and precipitated by adding 1 µl
linear acrylamide (0.1 µg/µl), 70 µl 7.5 M NH4Ac and 1
ml 200 proof ethanol, and centrifuged at 16,000 g for 20
min at room temperature. The pellet was washed in 500
µl 75% ethanol, centrifuged at 16,000 g for 5 min, air
dried and resuspended in 16 µl RNase-free water.
In vitro transcription of ds cDNA was performed using a
T7 MEGAscript™ kit (Ambion®). Four microliters of each
75 mM NTP, 4 µl of 10X reaction buffer and 4 µl of T7
polymerase mix was added to the 16 µl of ds cDNA. The
reaction was then carried out at 37°C for 5 hours. aRNA
was cleaned up using an RNeasy® mini kit (Qiagen®) as
described by the manufacturer.
The optimized version of the amplification protocol may
also be downloaded from  [http://www.stanford.edu/
group/sjeffreylab/].
RNA labelling and hybridization
Three micrograms of aRNA (unless otherwise specified) or
2 µg poly(A)+ RNA were labelled either with Cy5-dUTP
(experimental sample) or Cy3-dUTP (reference) in a 30.4
µl reaction. RNA was first mixed with either 8 µg of ran-
dom primer for aRNA or 5 µg of oligo(dT) primer for po-
ly(A)+ RNA in 16 µl of RNase-free water. RNA/primer mix
was incubated at 70°C for 10 min and cooled on ice for 2
min. The following reagents were added: 6 µl of 5X first
strand buffer, 3 µl 0.1 M DTT, 0.7 µl 50X dNTP (25 mM
dATP, dCTP, dGTP and 10 mM dTTP), 3 µl 1 mM Cy3-
dUTP or Cy5-dUTP and 1.7 µl Superscript™ II (200 U/µl).
The labelling reaction was carried out at 42°C for 2 hour
during which 1 µl Superscript™ II was added to the reac-
tion at the end of the first hour. The input RNA was hydro-
lyzed by adding 15 µl 0.1 M NaOH/2 mM EDTA and
incubated at 65°C for 8 min, followed by neutralization
with 15 µl 0.1 M HCl. The Cy5 and Cy3 labelled probes
were combined and purified in a Microcon® YM-30 col-
umn (Millipore) by washing three times with Tris-EDTA
buffer. 15 µg Human Cot-1 DNA was added to the probe
before the first wash. The purified probe was adjusted to a
total volume of 26 µl and mixed with 5.3 µl 20X saline-
sodium citrate (SSC), 1 µl yeast tRNA (10 µg/µl), 2 µl po-
ly(A) DNA (10 µg/µl), and 0.6 µl 10% sodium dodecyl
sulfate (SDS). The resulting 35 µl probe solution was de-
natured at 95°C for 2 min and then incubated at 42°C for
25 min. The probe was then hybridized to cDNA arrays at
65°C for 14–18 hours. Depending on the print batch, the
arrays contained from 42,772 to 43,915 spots (41,931–
42,602 distinct clones representing 16,907–18,417
named genes, 3946–4145 ESTs with known functions and
19,369–21,384 ESTs with unknown functions), and were
manufactured as previously described [31–33]. Following
hybridization, the arrays were washed with 2X SSC with
0.05% SDS once for 2 min at room temperature, 1X SSC
for 2 min at room temperature, 0.2X SSC three times for 1
min at 45–50°C.
Imaging and data analysis
The arrays with hybridized probes were scanned using an
Axon scanner. The scanned images were analyzed first us-
ing GenePix® Pro 3.0 software (Axon Instruments) and
spots of poor quality determined by visual inspection
were also removed from further analysis. The resulting
data collected from each array was submitted to the Stan-
ford Microarray Database (SMD,  [http://genome-
www5.stanford.edu/microarray/SMD]) [34]. A total of 97
arrays were submitted (60 experiments done with BC2
and 37 experiments performed with BC91). Only features
with a signal intensity >50% above background in both
Cy5 and Cy3 channels for all of the samples included in a
particular analysis were retrieved from SMD. Pearson's
correlation coefficient was calculated using Microsoft® Ex-
cel 2000. A components of variance model was used to ex-
plain different sources of variation in the amplification
protocols.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/31
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